Azitra adjourns 2026 annual meeting; only 17% of shares voted, needs 33.3% quorum

Azitra, Inc.

Meeting reconvened to June 15, 2026 at 11:00 a.m. ET; record date remains April 24, 2026.
Proxies received represented approx. 17% of outstanding shares; quorum requires 33⅓%.
No changes to proposals; stockholders can vote by mail, Internet, or phone until June 15 at 10:59 a.m. ET.
Company is a clinical-stage biopharma focused on precision dermatology; lead program ATR-12 for Netherton syndrome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.